ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Preclinical

Dihexa

Dihexa

Also known as: PNB-0408, Hepatocyte Growth Factor Mimetic

Overview

Key Facts

Primary Goal: A synthetic hexapeptide analog of angiotensin IV, developed at Washington State University

A synthetic hexapeptide analog of angiotensin IV, developed at Washington State University. Extraordinarily potent cognitive enhancer and neuroprotective agent, reported to be 10 million times more potent than BDNF at promoting synaptic connectivity. Half-Life ~6 hours (estimated) Typical Dose 10–40 mg Frequency 1x daily (oral or intranasal) Cycle Length 2-4 weeks, with breaks

Dosing Information

Half-Life

~6 hours (estimated)

Typical Dose

10–40 mg

Frequency

1x daily (oral or intranasal)

Cycle Length

2-4 weeks, with breaks

Administration Routes:

subcutaneousoral

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration2-4 weeks

Research Summary

Preclinical

Developed by Dr. Joseph Harding and colleagues at Washington State University. Published preclinical data demonstrates remarkable cognitive enhancement in scopolamine-impaired and aged rats. No human clinical trials completed. Patent filed for neurodegenerative disease applications. Safety profile in humans remains uncharacterized.

Frequently Asked Questions

Common questions about Dihexa

UK-Specific Information

Exclusive data points and guidance for UK residents using Dihexa

UK Lab Testing

US Lab Testing

Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With